Tenegliptin Sustained Release Tablet 10/500 mg

Adult dose

This medication is generally administered once daily with the evening meal. The 20/1000 mg sustained release tablet is taken once daily, 1 tablet each time. The 10/750 mg or 10/500 mg sustained release tablets are taken once daily, 2 tablets at the same time. The initial dosage should provide Tenegliptin 20 mg once daily along with the existing dosage of Metformin. When converting to a sustained release formulation, blood sugar control should be closely monitored.

This medication is used to treat diabetes but can rarely cause a serious condition called lactic acidosis. Lactic acidosis occurs when there is a dangerous buildup of lactic acid in the body, and if symptoms appear, medical attention should be sought immediately. This medication should not be administered to patients with moderate to severe renal impairment, and it is also not safe for patients with cardiovascular issues such as heart failure or acute myocardial infarction. Additionally, when undergoing exams with iodinated contrast agents, this medication should be stopped 48 hours prior to the exam, and should only be resumed once normal kidney function is confirmed. Women who are pregnant or may become pregnant, patients with severe liver impairment, and those with severe infections or traumatic systemic disorders are also advised against using this medication. When used in conjunction with insulin or sulfonylureas, there is an increased risk of hypoglycemia, so patients should be well-informed about the symptoms of hypoglycemia and take appropriate actions if symptoms occur. During treatment, it is essential to regularly monitor kidney function, especially in elderly patients or those with reduced kidney function. Furthermore, alcohol consumption should be avoided as it may increase the risk of lactic acidosis. Side effects can include gastrointestinal disturbances, dizziness, skin rashes, and joint pain. If serious side effects such as acute pancreatitis or interstitial pneumonia are suspected, medical advice should be sought immediately. Patients scheduled for surgery should discontinue this medication 48 hours prior to the procedure and can only resume once normal kidney function is confirmed after the surgery. If symptoms such as sudden abdominal pain, vomiting, difficulty breathing, or weakness occur during treatment, the physician should be notified immediately, as these may signal serious side effects. This medication has not established safety and efficacy in children and should not be used in nursing women.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pale skin, severe rash with high fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, shortness of breath or difficulty breathing, asthma attack, breathing difficulties with cough and fever, jaundice (yellowing of skin or eyes), profound lethargy, sudden and extremely severe headache, thunderclap headache, seizures, confusion, visual disturbances, paralysis, urination issues

Mild side effects

• Hypoglycemia
• constipation
• dizziness
• tremors
• headaches
• fatigue
• hunger
• facial swelling
• diarrhea
• dyspepsia

This medication should be stored in a tightly closed container to protect it from air and moisture. It should also be kept away from extreme temperatures, ideally at room temperature between 1 and 30 degrees Celsius.

Appearance

Orange oval shaped sustained release film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle